These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39069462)

  • 1. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
    Ren J; Huang Z; Tian J; Li Z; Shen S; Yan H; Wang N; Hu J; Ma X; Ma Z; Liu J; Lu Y; Sun X
    Vaccine; 2024 Aug; 42(21):126162. PubMed ID: 39069462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.
    Havers FP; Cho BH; Walker JW; Hariri S
    Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.
    Sartori AMC; de Soárez PC; Fernandes EG; Gryninger LCF; Viscondi JYK; Novaes HMD
    Vaccine; 2016 Mar; 34(13):1531-1539. PubMed ID: 26899375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis.
    Anyiwe K; Richardson M; Brophy J; Sander B
    Vaccine; 2020 Feb; 38(7):1825-1833. PubMed ID: 31889607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan.
    Hoshi SL; Seposo X; Okubo I; Kondo M
    Vaccine; 2018 Aug; 36(34):5133-5140. PubMed ID: 30041878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States.
    Kamiya H; Cho BH; Messonnier ML; Clark TA; Liang JL
    Vaccine; 2016 Apr; 34(15):1832-8. PubMed ID: 26899377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of pertussis booster vaccination for preschool children in Japan.
    Tanaka M; Okubo R; Hoshi SL; Ishikawa N; Kondo M
    Vaccine; 2022 Feb; 40(7):1010-1018. PubMed ID: 35039195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
    McCormack PL
    Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and Economic Evaluation of Vaccination Against Pertussis in China: A 40-Year Analysis.
    Wu D; Jing R; Zheng H; He K; Li Y; Yu W; Yin Z; Fang H
    Value Health; 2023 May; 26(5):666-675. PubMed ID: 36328326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.
    Cho BH; Acosta AM; Leidner AJ; Faulkner AE; Zhou F
    Prev Med; 2020 May; 134():106066. PubMed ID: 32199910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
    Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
    Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
    Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.